MDRNA Granted Continued Nasdaq Listing; Issues Prospectus to Sell $12.5M in Stock and Warrants | GenomeWeb

MDRNA announced this week that the Nasdaq Stock Exchange has granted the company's request to remain listed on its Global Market until Aug. 31, when it must meet the exchange's minimum $10 million stockholder's equity requirement or demonstrate a greater than $50 million market value of listed securities.

"We are pleased that NASDAQ has granted our request to remain on The NASDAQ Global Market," MDRNA President and CEO Michael French said in a statement. "We remain confident that our plan to regain compliance … is achievable well before August 2009."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.